Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
JSPR

JSPR - Jasper Therapeutics, Inc. Stock Price, Fair Value and News

$0.49+0.02 (+4.26%)
Delayed as of 10 Jun 2026, 10:51 am ET

81/100

JSPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

JSPR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

JSPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JSPR Price Action

Last 7 days

-16.4%

Last 30 days

-50.5%

Last 90 days

-65.7%

Trailing 12 Months

-92.3%

JSPR RSI Chart

JSPR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

JSPR Valuation

Market Cap

13.2M

Price/Earnings (Trailing)

-0.24

Price/Sales (Trailing)

5.86

EV/EBITDA

-3.13

Price/Free Cashflow

-0.19

JSPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

JSPR Fundamentals

JSPR Revenue

Revenue (TTM)

4.0M

JSPR Earnings

Earnings (TTM)

-55.7M

Earnings Growth (Yr)

94.47%

Earnings Growth (Qtr)

87.1%

JSPR Profitability

Operating Margin

-635.39%

EBT Margin

-86.28%

Return on Equity

-1.6K%

Return on Assets

-263.09%

Free Cashflow Yield

-523.32%

JSPR Investor Care

Shares Dilution (1Y)

86.37%

Diluted EPS (TTM)

-2.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.0M000
20233.0M3.5M00
20221.9M2.5M00
2021901.3K1.4M00
2020000383.1K
20190000
Get all data in R, Python etc through our Historical Stock Data APIs

About Jasper Therapeutics, Inc.

JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
 CEO
 WEBSITEjaspertherapeutics.com/
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES35

Jasper Therapeutics, Inc. Frequently Asked Questions

JSPR is the stock ticker symbol of Jasper Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jun 09 2026, market cap of Jasper Therapeutics, Inc. is 13.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Jun 09 2026, JSPR's PE ratio (Price to Earnings) is -0.24 and Price to Sales (PS) ratio is 5.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JSPR PE ratio will change depending on the future growth rate expectations of investors.